Regulus Therapeutics Inc. (RGLS) Fundamentals

Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. MicroRNA is a noncoding ribonucleic acid that regulates most genes in the genome. The company partnered with Sanofi to create a compound targeting orphan diseases and with AstraZeneca to cure Type 2 Diabetes/prediabetes.
SHARE INFORMATION
Market Cap$ 25,317,536
Shares Outstanding14,634,414
Float11,109,937
Percent Float75.92%
Short Interest0.00
Short Percent Float0.0%
Short Interest Ratio0.00
Short Interest Date-
Latest Fiscal Dividend Per Share$ 0.00
Latest Fiscal Revenue$ 0
Latest Fiscal EPS$ -3.18
Latest Fiscal Date2021-12-31
DIVIDENDS
Dividend (3 Years)$ 0.00
Dividend (5 Years)$ 0.00
Ex Dividend Date-
Dividend Rate$ 0.00
Dividend Yield0.0%
Payment Cash-
HOLDERS
Institutions63
Institutional Holdings Date2022-07-31
Institutional Bought Previous 3 Months19,595,984
Institutional Holdings Percent136.2%
Institutional Sold Previous 3 Months144,754
Insider Holdings Date2022-07-31
Insider Bought Previous 3 Months1,230,000
Insider Holdings Percent41.0
Insider Sold Previous 3 Months-
Insider Shares Owned5,979,399
TRADING INFO
52 Week High$ 8.72
52 Week Low$ 1.42
52 Week High Change$ -74.57
21 Day Moving Average$ 1.6786
21 Day Extended Moving Average$ 1.7632
50 Day Moving Average$ 2.0568
50 Day Extended Moving Average$ 1.9617
200 Day Moving Average$ 2.6834
200 Day Extended Moving Average$ 3.2044
10 Day Average Volume166,797
20 Day Average Volume142,006
30 Day Average Volume120,009
50 Day Average Volume114,235
Alpha-0.054595
Beta1.9778
Standard Deviation0.273673
R20.130656
7 Day Price Change$ 0.08
7 Day Percent Change4.85%
21 Day Price Change$ 0.13
21 Day Percent Change8.13%
30 Day Price Change$ -0.35
30 Day Percent Change-16.83%
Month to Date Price Change$ 0.12
Month to Date Percent Change7.45%
Quarter to Date Price Change$ -0.34
Quarter to Date Percent Change-16.43%
180 Day Price Change$ -0.57
180 Day Percent Change-24.78%
200 Day Price Change$ -0.4845
200 Day Percent Change-21.88%
Year to Date Price Change$ -1.42
Year to Date Percent Change-45.08%

Regulus Therapeutics Inc. (RGLS) Key Ratios

PROFITABILITY
EBIT Margin-419.1%
EBITDA Margin-408.7%
Pre-Tax Profit Margin-33,658.7%
Profit Margin Count-79.86%
Gross Margin0.0%
Profit Margin TOT-79.86%
INCOME STATEMENTS
Revenue$ 0
Revenue Per Share$ 0.00
Revenue (3 Years)$ 0.00
Revenue (5 Years)$ 0.00
FINANCIAL STRENGTH
Price to Tangible Book0.60
Total Debt To Equity0.20
Int Coverage-39.10
Current Ratio8.80
Leverage Ratio1.30
Quick Ratio8.20
Long Term Debt To Capital0.10
VALUATION MEASURES
PE Ratio-0.70
Enterprise Value$ -15,809,808
Price to Sales0.00
Price to Free Cash-1.00
PE High Last 5 Years-0.30
Price To Book0.60
Price To Cash Flow0.00
PE Low Last 5 Years-0.60
Price to Tangible Book0.60
MANAGEMENT EFFECTIVENESS
Receivables Turnover0.00
Invoice Turnover0.00
Assets Turnover0.00
Return Assets-60.66
Return on Equity-79.40
Return on Capital-63.08

Regulus Therapeutics Inc. (RGLS) Profile

PROFILE INFO
Issue TypeCS
SEC TypeEQS
AuditorErnst & Young LLP
CEOJoseph P. Hagan
Emplyoees25
Last AuditUQ
CIK0001505512
IndustryBiotechnology
SectorHealthcare
NAICSPharmaceutical Preparation Manufacturing(325412)
CONTACT INFO
Address4224 Campus Point Court
Suite 210
San Diego, CA 92121
Websitehttps://www.regulusrx.com
Facsimile-
Telephone+1 858 202-6300
Emailinformation@regulusrx.com


Your Recent History
NASDAQ
RGLS
Regulus Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.